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After a screening visit, 20 patients with COPD (mean FEV1 49% pred) were treated
with cetirizine 10mg daily or placebo over 1 week in a randomized, double-blind,
cross-over fashion and measurements performed at the end of treatment periods. At
each visit, patients were challenged by 3% saline aerosol (screening: 0.9%) over 5min
after prior inhalation of salbutamol, and 45min later sputum was obtained after
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Spirometric values did not differ between visits and salbutamol-induced
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salbutamol values, the saline-induced fall in FEV1 was smallest at screening
(Po0:01), without a significant difference between treatments. Regarding FIV1,
however, the percent fall from baseline was higher after placebo (D ¼ 10:1%;
Po0:05) compared to screening (0.4%) or cetirizine (4.3%). Sputum compositionElsevier Ltd. All rights reserved.
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L. Gro¨nke et al.1242showed no significant differences except for a tendency towards reduced
concentrations of a2-macroglobulin after cetirizine compared to placebo
(P ¼ 0:045).
The present data indicate some, though small, effects of the H1 receptor
antagonist cetirizine on hypertonic saline-induced airway obstruction in patients
with moderate-to-severe COPD. In view of the mechanisms involved, it is an open
question whether stronger effects can be elicited with higher doses and whether
such effects would translate into clinical benefits, e.g. during exacerbations.
& 2005 Elsevier Ltd. All rights reserved.Table 1 Patients’ characteristics.
Sex (f/m) 3/17
Age (y) 6274
Weight (kg) 93721
BMI (kg/m2) 29.275.8
Smoking history (Packyears) 56726
FEV1 (L) 1.5970.27
FEV1 (% pred) 48.877.8
FIV1 (L) 3.0570.56
IVC (L) 3.5070.63
FEV1/FVC (%) 48.578.4
ITGV (% pred) 142.97 30.3
RV/TLC (%) 54.074.7
TLCO (% pred) 71.5722.2
Arithmetic mean values7SD are given. BMI: Body Mass
Index; FEV1: forced expiratory volume in 1 s; FIV1: forced
inspiratory volume in 1 s; IVC: inspired vital capacity;
FEV1/FVC : ratio of forced expiratory volume in 1 s to
forced vital capacity; ITGV: intrathoracic gas volume; RV/
TLC: ratio of residual volume to total lung capacity; TLCO:
single breath diffusion capacity for carbon monoxide.Introduction
Inhalation challenges using hypertonic saline aero-
sol have been used in asthma research for a long
time1 but are less commonly performed in patients
with chronic obstructive pulmonary disease
(COPD). In most cases the challenge has been more
or less inadvertently used during sputum induction
which requires inhalation of hypertonic or isotonic
saline solution by a high-output nebuliser. Patients
with COPD, particularly those with more severe
disease, are known to develop significant airway
obstruction during this procedure2,3 and the re-
sponse to hypertonic saline aerosol has already
been used to address bronchoprotective effects of
a leukotriene receptor antagonist4 or inhaled
corticosteroids5 in this disease.
More detailed data on drug effects are available
in asthma, in which cyclooxygenase inhibitors6
and cromones7 have shown the potential to re-
duce hypertonic saline-induced airway obstruction.
Corticosteroids could also attenuate the res-
ponse in asthma.8 Interestingly, in patients with
COPD their beneficial effect seemed to be due
solely to increased bronchodilation by salbutamol
which had been administered before the chal-
lenge.5 In accordance with this, a leukotriene
receptor antagonist exerted a protective effect
particularly in severe COPD, independently from
the presence of steroids.4 In asthma there are
also results showing a protective capacity for
anti-histamines,6,9 but no corresponding data
exist in COPD. Such data seem to be of interest,
as there is release of mediators such as histamine3
and probably cysteinyl leukotrienes during hyper-
tonic saline challenge in COPD, in line with
the effect of an anti-leukotriene.4 In addition,
data in COPD could be of interest for clinical
purposes. Though it is unknown whether the
response to hypertonic saline represents an effect
encountered under real-life conditions, we have
previously compiled arguments that it could mimic
part of the functional effects occurring during
exacerbations.4Based on these considerations we performed a
trial using short-term treatment with the H1
histamine receptor antagonist cetirizine dihy-
drochloride to determine its effect on the airway
response to hypertonic saline aerosol in patients
with moderate-to-severe COPD.Materials and methods
Patients
Twenty patients with the diagnosis of moderate-to-
severe stable COPD10 and FEV1p60% of predicted
normal values11 were enrolled into the study
(Table 1). Patients were of GOLD stage II (n ¼ 9) or
III (n ¼ 11),10 exsmokers since at least 6 weeks and
had no history of asthma or allergic disease. All
patients inhaled b2-adrenoceptor agonists and/or
short-acting anti-cholinergics on a regular basis,
while none of them had long-acting anti-cholinergics
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Cetirizine hypertonic saline and COPD 1243at the time of the study. Five patients took
theophylline and nine received inhaled but not
systemic corticosteroids; the latter had to be
discontinued at least 4 weeks before inclusion.
Medication was held constant over the whole course
of the trial. The study was approved by the local
Ethics Committee and all patients gave their written
informed consent.Study design
The study comprised a screening visit and two visits
at the end of two consecutive treatment periods.
Patients were asked to stop the inhalation of short-
or long-acting b2-agonists for at least 6 or 12 h,
respectively, and that of short-acting anti-choli-
nergics at least 6 h before measurements, while
maintaining all other medication including inhaled
corticosteroids and theophylline.
The screening visit was used to assess medical
history and clinical state as well as lung function
values. Challenges with saline aerosol were per-
formed as
’ ’
twin challenges’’ separated by 45min,
whereby the first inhalation was used for provoking
the lung function response and the second inhalation
for inducing sputum. Prior to the first inhalation,
patients inhaled 200mg salbutamol, and 10min later,
after further lung function measurement, they
inhaled 0.9% saline for 5min. The aerosol was
generated by an ultrasonic nebuliser (NE-U12,
Omron, Tokyo, Japan) as used in sputum induction.12
Lung function was measured 2, 5, 15, 25, 35 and
45min after inhalation to monitor the acute
response as well as recovery. The second inhalation,
again of 0.9% saline and comprising two consecutive
5-min inhalation periods, was started after the last
measurement had been performed (45min). Lung
function was monitored until 25min afterwards.
Patients were then randomized to a double-
blind, cross-over treatment with either 10mg
cetirizine dihydrochloride twice daily or placebo
over a time period of 1 week (7–10 days) duration.
The short treatment period was chosen to improve
patients’ compliance, as we expected effects of
the anti-histamine to occur within short time.
Treatment periods followed immediately one after
the other and the resulting washout period of about
1 week was considered adequate from available
data.13 Patients used their regular medication
during both treatment periods.
At the end of each period, they visited the
laboratory again for the assessment of clinical state
and lung function. The procedure followed at
screening, including inhalation of salbutamol and
two saline inhalations 45min apart, was performedagain. However, different from screening, 3% saline
was administered in the first 5-min challenge,
whereas the second inhalation 45min later again
used 0.9% saline over 2 5min.Measurement of lung function
Forced expiratory volume in 1 s (FEV1) was assessed
following established guidelines14 using a pneumo-
tachograph (Masterlab, Jaeger, Wu¨rzburg, Ger-
many). In addition, the forced inspiratory volume
in 1 s (FIV1) was determined following previously
defined criteria.15 Inspired vital capacity (IVC),
intrathoracic gas volume (ITGV), the ratio of
residual volume to total lung capacity (RV/TLC)
and the transfer factor for carbon monoxide (TLCO)
were additionally measured upon inclusion.Sputum analysis
Patients were asked to produce sputum after the
two 5-min periods of inhaling 0.9% saline that took
place 45min after the first challenge. Basically,
sputum processing followed previously used proce-
dures.12 Material that could be recognised macro-
scopically as originating from the lower airways was
separated from saliva under a microscope. Samples
were homogenised by mixing one part of sputum
with two parts of 0.1% dithiothreitol (Sputolysins)
according to weight, incubated for 15min at 37 1C
and diluted by addition of phosphate-buffered
saline (PBS) to achieve a 20-fold dilution. Samples
were then centrifuged twice at 4 1C. The resulting
supernatants were stored at 80 1C until analysis.
After thawing, the concentration of a2-macroglo-
bulin, as a potential marker of protein leakage, was
determined.16 From the cell pellet cytospin slides
were prepared and stained with Giemsa reagent.
Differential cell counts were obtained from
400–500 cells by two observers on coded slides
and mean values of the two counts were taken for
analysis.Data analysis
For all variables, arithmetic mean values were
computed. Standard deviations (SD) were chosen for
describing the study population, whereas standard
errors (SEM) were used to quantify the variability of
responses. Median values and interquartile dis-
tances were chosen in case of markedly skewed
distributions. Both absolute and percent values of
changes in FEV1 and FIV1 were computed to
evaluate effects of inhalations or medication.
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L. Gro¨nke et al.1244For comparison of the three visits repeated-
measures ANOVA was employed followed by New-
man–Keuls post hoc multiple comparisons where
appropriate. The paired t-test was used when only
two values were involved, such baseline values and
values assessed after recovery. Comparisons re-
garding the concentration of a2-macroglobulin were
performed by the unpaired t-test. P-values refer to
either ANOVA overall results (Table 2), or pairwise
or multiple comparisons (Results). Statistical sig-
nificance was assumed for Po0:05:Results
During the course of the study, no significant
adverse events occurred and patients remained in
a stable state without exacerbations that could
have affected responses. Medication containers as
returned after the study indicated acceptable
compliance and showed on average 92% of the
predicted weight reduction. Furthermore, the
results did not depend on treatment order (placebo
first: n ¼ 9).
Baseline values and bronchodilator response
to salbutamol
Baseline values of FEV1 and FIV1 did not show
significant differences between the three study
visits (Table 2). Inhalation of salbutamol caused
bronchodilation in terms of both FEV1 and FIV1 at
all three visits (Po0:001 each; Figs. 1 and 2).
Neither the absolute values of FEV1 measured after
salbutamol inhalation nor the absolute or percent
changes from baseline showed significant differ-
ences between the three visits. The same was true
for FIV1.
Response to hypertonic saline inhalation
(first inhalation)
The lowest values of FEV1 and FIV1 occurred 2min
after the saline challenge (Figs. 1,2); these values
did not significantly differ between visits (Table 2).
In contrast, the changes induced by saline inhala-
tion were different. Specifically, absolute and
percent changes of FEV1 relative to baseline
showed a difference between screening on one
hand and both study visits on the other (New-
man–Keuls, Po0:05 each; Table 2), indicating a
stronger response to 3% compared to 0.9% saline
irrespective of medication. Mean percent changes
were +6.1% at screening, 1.7% after placebo, and
1.5% after cetirizine. Regarding FIV1, absolute
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Figure 2 Analogous to Fig. 1 but data on FIV1 are given.
For statistical significance of ANOVA, see Results.
           Time after challenge (min)
F
E
V 1 (
L)
1 .4
1 .5
1 .6
1 .7
1 .8
1 .9
2 .0
B S 2 5 1 5 t 3 5 4 5
Figure 1 Mean values7SEM of the time course of FEV1
from baseline (B) to values measured 10min after
inhalation of 200 mg salbutamol (S) to values observed
2, 5, 15, 25, 35 and 45min after a 5-min saline inhalation
(first inhalation of twin challenge). Filled circles indicate
the results obtained after treatment with cetirizine and
open circles those after placebo. These two challenges
used 3% saline aerosol. Open triangles indicate the values
obtained upon screening using 0.9% saline aerosol. For
statistical significance of ANOVA, see Results.
Cetirizine hypertonic saline and COPD 1245changes showed a significant difference between
screening and placebo only (Po0:01). In contrast,
percent changes after placebo (10.1%) were
significantly (Po0:05) greater than both the effects
observed after cetirizine (4.4%) and those at
screening (0.4%), thus indicating a protective
effect of cetirizine in terms of FIV1.
When expressed as absolute or percent change of
FEV1 relative to post-salbutamol values, there was
again a difference between screening vs. both
medications (Po0:05 each; Table 2), demonstrating
the greater response after 3% compared to 0.9%
saline. Absolute changes of FIV1 differed between
screening and placebo (Po0:05), with cetirizine inbetween, whereas percent changes were not
significantly different between visits.
Recovery and response to isotonic saline
inhalation (second inhalation)
The absolute values of either FEV1 or FIV1 as
measured 45min after the hypertonic saline chal-
lenge did not significantly differ between the three
study visits (Figs. 1,2). Compared to baseline values
there were improvements of FEV1 at screening and
after placebo (paired t-test, Po0:05 each), but
there were no changes regarding FIV1. Post-salbu-
tamol values of FEV1 or FIV1 were not significantly
different from 45-min values.
According to FEV1 there was significant (Po0:05
each) bronchoconstriction after the second chal-
lenge comprising inhalation of 0.9% saline over
2 5min. Changes were on average 6.6% at
screening, 6.4% after placebo and 4.4% after
cetirizine. There were no significant changes in
FIV1. With both placebo and cetirizine, values of
FEV1 and FIV1 observed 25min after inhalation were
no more different from those observed before
(45min after the first challenge), but there
remained a small difference at screening (4.3%,
P ¼ 0:032), indicating incomplete recovery.
Sputum analysis
Due to lack of material of sufficient quality and/or
quantity, a number of sputum samples could not be
evaluated with regard to cell numbers and/or
supernatants. For cell differentials, 40/60 samples
yielded results with a comparable distribution
between visits. There were no statistically signifi-
cant differences between the three sputum sam-
ples regarding total cell counts, or the percentages
of neutrophils, macrophages, or lymphocytes. The
mean (7SEM) percentage of neutrophils was
65.779.3% at screening, 57.678.2% after placebo,
and 65.077.8% after cetirizine. The respective
percentages of eosinophils (median and interquar-
tile distance due to skewed distribution) were 0.6
(5.4), 1.5 (10.7) and 0.5 (1.5) %. Total cell counts
were 4.18 (13.7), 5.26 (11.5) and 4.15
(4.0) 106 cells/mL, respectively.
Figure 3 shows the data of a2-macroglobulin that
could be evaluated (33/60). Since only few patients
had samples at all visits, statistical comparisons
were performed using a one-tailed test for inde-
pendent samples. We considered this approach
applicable in a tentative analysis, as the pattern
of missing values appeared to be random and as we
expected protection if there should be any effect
ARTICLE IN PRESS
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Figure 3 Individual data and median values (horizontal
bars) of the concentration of a2-macroglobulin in sputum
supernatants obtained 45min after the first inhalation
challenge by inhalation of 0.9% saline over 2 5min (see
Results for details and statistical comparison).
L. Gro¨nke et al.1246at all. The tendency towards a protection by
cetirizine as suggested by Fig. 3 could be sub-
stantiated insofar as there was a difference
between the levels observed after placebo and
cetirizine (P ¼ 0:045). Median values were 346, 625
and 278 ng/mL at baseline, after placebo and after
cetirizine, respectively.Discussion
In the present study, we used hypertonic saline
aerosol for bronchial challenge in patients with
moderate-to-severe COPD to assess the effect of a
1-week treatment with 10mg cetirizine dihy-
drochloride per day versus placebo. To ensure
comparability with the procedure of sputum induc-
tion as well as previous studies, salbutamol was
administered prior to the hypertonic saline chal-
lenge.3–5 The bronchodilator effect of salbutamol
was not altered by cetirizine. In accordance with
previous findings, salbutamol did not prevent air-
way obstruction3–5 and 3% saline caused greater
obstruction than 0.9% saline,3 in terms of forced
expiratory volumes. Different from that, the
analysis of forced inspiratory manoeuvres sug-
gested that the airway obstruction elicited by 3%
saline could be attenuated by cetirizine. In addi-
tion, there was a tendency towards a reduction of
the concentration of a2-macroglobulin in sputum
supernatants, suggesting attenuation of plasma
extravasation and airway edema that is thought
to be caused by the hypertonic saline challenge.4,17
Though the effects of cetirizine dihydrochloride
were small, the direction of changes was consistent
with the hypothesis that plasma leakage plays arole in hypertonic saline-induced airway obstruc-
tion in severe COPD.
Functional responses were quantified by FEV1 and
FIV1. FIV1 appears to be well suited for the
assessment of bronchodilation in severe COPD, as
it avoids the expiratory airway collapse which can
mask the bronchodilator response.15 In contrast,
bronchoconstriction is reflected in both FEV1 and
FIV1.
3 In accordance with previous data we ob-
served stronger responses after inhalation of 3%
compared to 0.9% saline aerosol3 and these
differences were particularly clear in terms of
FEV1 (Fig. 1). Most patients felt the forced
expiratory manoeuvres less demanding than the
forced inspiratory manoeuvres; thus variability of
repeated measurements was slightly larger for FIV1
than for FEV1.
18
The present data indicated some protective
effect of cetirizine when analysing the hypertonic
saline-induced fall in FIV1 (Fig. 2). One potential
problem when using FIV1 is a ceiling effect in
patients with only moderate airway obstruction: as
forced inspiration is nearly completed within 1 s
and thus close to IVC, FIV1 becomes rather
insensitive to changes in bronchial tone, in contrast
to patients with severe obstruction. Inspection of
Fig. 2 suggests that salbutamol inhalation always
led to a comparable increase of FIV1 and that the
greater saline-induced fall observed after placebo
compared to cetirizine was not due to a ceiling
effect. The difference between the time course of
FEV1 (Fig. 1) and FIV1 (Fig. 2) was striking. There
was a small, statistically not significant difference
in baseline values of FIV1 and slightly more
variability compared to FEV1.
18 Nonetheless the
fall in FIV1 induced by hypertonic saline turned out
to be significantly different between both medica-
tions, even when applying a conservative post hoc
test according to Newman–Keuls that accounted for
multiple comparisons.
The effect of H1 receptor antagonists on hyper-
tonic-saline induced bronchoconstriction has been
studied previously in asthma.6,9 Obstructive re-
sponses in terms of the percent fall in FEV1 were
greater than in the patients with COPD studied by
us, and at the same time protection by terfenadine
was stronger.6 Similar data were obtained for
clemastine.9 It is not clear whether the obstruction
elicited by hypertonic saline aerosol is based on the
same mechanisms in asthma and COPD. In patients
with asthma and nearly normal lung function, the
primary cause is probably mast cell activation with
subsequent smooth muscle contraction. In patients
with severe COPD, however, nonspecific reactivity
of bronchial smooth muscle appears to be lower
than normal.19 In view of the severely reduced
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Cetirizine hypertonic saline and COPD 1247airway lumen, other mechanisms might come into
play, among them acute airway edema. Airway
edema can be elicited by hypertonic saline aero-
sol,17 and the response is largely mediated by
neuropeptides in concert with cysteinyl leuko-
trienes and histamine.20 Osmotic stimuli can lead
to the release of these compounds21 and mast cells
are responsive to osmotic stimuli, though their
responses differ between mediators.22 This might
well explain the attenuation of the obstructive
airway response by an anti-leukotriene in severe
COPD,4 in line with the findings of elevated levels
of histamine3 and substance P23 in the sputum of
patients with COPD or chronic bronchitis after
hypertonic saline challenge.
Thus there might be a role for anti-histamines
with regard to the attenuation not only of smooth
muscle contraction but also of plasma extravasa-
tion. It is of particular interest that H1 receptor
antagonists demonstrated inhibitory effects on
plasma extravasation in animals only in large
airways.24,25 Forced expiration is likely to be more
dependent on small airways obstruction than
forced inspiration, and the manoeuvre of forced
inspiration has long been known to be valuable for
the detection of upper airways obstruction.26 In
accordance with this differential effect and sensi-
tivity, there was no effect of cetirizine on the
course of FEV1 (Fig. 1), whereas some protection
was discernible in FIV1 (Fig. 2). This was just the
converse of the result observed with a leukotriene
receptor antagonist,4 where effects were more
pronounced in FEV1 than FIV1, although patients
had more severe disease and thus more room for
change in FIV1 than the patients of the present
study. The effect of cetirizine was not different
between patients with and without inhaled corti-
costeroids. Furthermore, when comparing re-
sponses between the two subgroups with FEV1 of
either 449% or p49% predicted (median value of
study population), the effect of cetirizine was
observed only in patients with better lung function,
different from the leukotriene receptor antago-
nist.4 This could point towards an additional effect
on smooth muscle as probably occurring in asthma,
or indicate insufficient dosing or a minor role for
histamine compared to other mediators in more
severely ill patients.
We assessed the concentration of a2-macroglo-
bulin in airway secretions as a potential marker of
plasma protein leakage, though we did not have the
opportunity to measure the concentrations of other
proteins as a reference.1,27 Unfortunately sputum
samples were insufficient in a considerable number
of cases, preventing even the determination of a2-
macroglobulin. We believe that the concept of the’ ’
twin challenge’’, comprising a first challenge for
assessing obstruction and a second one for obtain-
ing sputum, was responsible for this failure. The
idea behind this concept was to provide more time
for the release of mediators and markers into
airway secretions. Probably, however, patients
unwillingly produced sputum after the first chal-
lenge and swallowed the material, with the result
that sputum production was handicapped in the
second challenge. As we had not encountered
problems in repeated sputum productions in pre-
vious work,2 the twin challenge was incorporated
into the study protocol. It is well possible that in
the present study the repeated lung function
measurements including forced inspiratory and
expiratory manoeuvres have promoted an unde-
sired effect on sputum production. Despite the
handicap posed by incomplete values, there was a
tendency towards elevated levels of a2-macroglo-
bulin after inhalation of 3% compared to 0.9%
saline, and in particular towards a reduction after
treatment with cetirizine (Fig. 3). The result is
consistent with the hypothesis of hypertonic saline-
induced plasma protein leakage and a beneficial
effect of the H1 receptor antagonist on this
response. This is true, even if the effect should
have been restricted to the larger bronchi, as
sputum originates from this region.12 If one adopts
the views outlined above, the observed effects of
cetirizine, small as they were, appeared to fit into
a consistent picture of hypertonic-saline-induced
airway obstruction in COPD.
In conclusion, the present data indicate some,
though small, effects of the H1 receptor antagonist
cetirizine on hypertonic saline-induced airflow
obstruction in moderate-to-severe COPD. In view
of the mechanisms involved in hypertonic saline
responses, it is an open question whether stronger
effects can be elicited with higher doses and
whether such effects would translate into clinical
benefits, e.g. during exacerbations.Acknowledgements
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